Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 8 July 2025, 08:31 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

TOKYO, July 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been selected for the highest rating of “Supplier Engagement Leader” in the Supplier Engagement Rating by the global environmental non-profit organization CDP.(1)

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues. In its responses to the CDP Climate Change Questionnaire on 'Governance', 'Targets', 'Scope 3 emissions(2)' and 'Value chain engagement', Eisai’s efforts to engage with suppliers were highly regarded, leading to this selection. To conduct environmentally conscious business activities throughout our entire supply chain, Eisai asks business partners to comply with the “Eisai Global Code of Conduct for Business Partners(3)” which clearly states Eisai’s requirement for environmental conservation. Collaboration with suppliers is also strengthened by conducting sustainability assessments of partners and providing feedback on the results.

Eisai identifies “Business activities with consideration for the global environment” as one of its material issues. Based on the “Eisai Network Companies Environmental Protection Policy”, Eisai is promoting responses to climate change as key environmental activities across the group. Eisai is working towards the realization of a decarbonized society, including receiving approval for the SBT 1.5°C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI)Race to Zero Circle, which calls for achieving net zero by 2050.(4)

Please refer to Eisai’s website for more detailed information about its environmental activities.

The preservation of the global environment is essential for realizing Eisai’s corporate concept of human health care (hhc). Eisai will contribute to empowering people to “realize their fullest lives” through our climate change initiatives.

(1)A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system.
(2)Indirect greenhouse gas emissions across the entire corporate value chain
(3)Please refer here for further details
(4)Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GASREDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050
https:/www.eisai.com/news/2024/news202412.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

 




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 17, 2026 23:24 HKT/SGT
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 15, 2026 23:18 HKT/SGT
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15, 2026 22:51 HKT/SGT
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15, 2026 22:21 HKT/SGT
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13, 2026 23:06 HKT/SGT
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 2, 2026 21:45 HKT/SGT
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 2, 2026 21:01 HKT/SGT
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
June 17, 2026 12:28 HKT/SGT
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
May 21, 2026 23:23 HKT/SGT
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 19:52 HKT/SGT
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: